Background In order for vitamin D to signal and regulate inflammatory pathways, it must bind to its receptor (VDR) which must heterodimerize with the retinoid X receptor alpha (RXRa). Although the role that vitamin D signaling plays in the development and progression of colitis, a disease characterized by excessive inflammation, has been suggested, little research has been done on determining the role that RXRa plays in acute colitis development. Aims This study sought to determine the effects that reduced availability of RXRa would have on the development of acute murine colitis. Expression of inflammatory markers, VDR and RXRa were investigated to determine if the reduction in expression of RXRa in RXRa ?/-mice would result in increased inflammatory signaling and receptor downregulation as compared to their wild-type littermates.
Introduction
Retiniod X receptor alpha (RXRa), the receptor for 9-cis retinoic acid [1] , is a member of the steroid nuclear receptor super family [2, 3] . RXRa is required by numerous receptors, including the vitamin D receptor (VDR) and the peroxisome proliferator-activated receptor gamma (PPARk) as a heterodimerization partner. Without RXRa to heterodimerize with, these receptor would not be able to allow their ligands to influence cellular signaling.
Vitamin D signals though VDR to control many pathways, including inflammation. After VDR and RXRa bind to their respective ligands and heterodimerize, they move to interact with vitamin D response elements (VDRE) in DNA. When binding VDRE, VDR binds the 3 0 half-site and RXRa binds the 5 0 half-site [4] . If this binding is reversed, gene repression results [5, 6] . Thus, RXRa availability and functionality is required for vitamin D to regulate gene expression [7] . Vitamin D has been linked to cancer development and progression through its regulation of proto-onco and tumor-suppressor genes [8] [9] [10] [11] [12] , yet its role in disease states that can ultimately progress to cancer, such as colitis, remains less understood.
Ulcerative colitis (UC) is an inflammatory disease of the colon that can ultimately progress to colitis-associated cancer (CAC). The importance of vitamin D in colitis development was first proposed when it was observed that as distance from the equator increases, the prevalence of colitis also increases [13] . Up to 50 % of UC patients suffer from vitamin D deficiency with around 10 % having a severe deficiency that can impact quality of life [14] . It has yet to be determined if the observed vitamin D deficiency is a cause, effect, or both, of UC development and progression.
The roles of RXRa and PPARk in colon homeostasis and colitis development have been illustrated through in vivo experiments. PPARk ligands, thiazolidinediones, were able to ameliorate the dextran sulfate sodium (DSS) and 2,4,6-trinitrobenzene sulfonic acid (TNBS) models of colitis in mice [15] [16] [17] [18] . RXRa agonists were also effective at reducing TNBS induced colitis with a synergistic effect observed when combined with PPARk agonists. PPARk ?/-and RXRa ?/-mice demonstrated an increased susceptibility to TNBS induced colitis [18] . However, the majority of this work was done in the TNBS model which more closely resembles Crohn's Disease with little research using the DSS model which models UC.
Our laboratory has demonstrated that VDR is downregulated in murine colitis and that RXRa is downregulated in colon cancer cell lines, colorectal cancer [19] , murine colitis and CAC [20] . The downregulation of VDR has been linked to Snail and Snail2, zinc-finger transcription factors [21] [22] [23] that are upregulated or stabilized by inflammatory mediators [24] [25] [26] [27] [28] . Snail and Snail2 are expressed in diseased tissue of UC and colorectal cancer (CRC) and their expression corresponds to a localized downregulation of VDR [22, [29] [30] [31] . No definitive mechanism for the downregulation of RXRa has emerged.
To investigate the role that RXRa plays in regulating inflammatory signaling and colitis development, RXRa ?/-mice and their wild-type littermates were challenged with the well characterized azoxymethane (AOM) and dextran sulfate sodium (DSS) model of UC. An acute model was chosen to elucidate changes that occur early in colitis development. Gross manifestations of colitis were measured to determine if heterozygotes were less capable of withstanding the AOM/DSS challenge. The expression of VDR and RXRa mRNA and protein, along with the mRNA of inflammatory markers and Snail and Snail2 were analyzed. These experiments demonstrate, for the first time, the importance of RXRa in regulating inflammatory markers activated in the AOM/DSS colitis model.
Materials and Methods

Mice
RXRa
?/-mice and their wild-type littermates were a gift from Dr. Steven Kublalak (Medical University of South Carolina, Department of Regenerative Medicine and Cell Biology). Geneotyping was performed in Dr. Kubalak's lab prior to transfer. These mice were induced to have acute colitis with 11 heterozygote or wild-type littermates per treatment modality (colitis or control). Mice were cared for within Institutional Animal Care Committee (IACUC) guidelines and all procedures were approved by the Medical University of South Carolina (MUSC) IACUC. Mice were housed in groups of five at 22-24°C using a 12 h light-12 h dark cycle with lights on at 06:00. Animals were fed normal chow for the duration of the experiment (Harlan Teklad Diet 2918).
Induction of Colitis
To induce colitis, DSS (MW 36,000-50,000 D, MP Biomedical, Santa Ana, CA) and AOM (Sigma-Aldrich, St. Louis, MO) were utilized. Twenty-two heterozygote and 22 wild-type mice were divided into control and treatment groups based on sample size calculations. For the acute AOM/DSS model, mice were allowed to acclimate for 1 week and were then injected intraperitoneally with 10 mg/kg AOM or saline (control) on day eight. The mice recovered for 1 week with water, and on day fifteen, the mice injected with AOM were given 2 % DSS in water for 7 days and the mice injected with saline remained on normal water. The mice were sacrificed on the seventh day of the DSS/water treatment.
Study Design
Eleven heterozygote or wild-type mice were used per treatment group (colitis or control). The colons from six mice were used for RNA and protein extraction and the remaining five mice had their colons Swiss-rolled as described [32] for colitis scoring. All experiments were done in biological and technical duplicates.
Sacrifice and Tissue Harvesting
Mice were sacrificed via CO 2 inhalation followed by cervical dislocation. Blood was removed via cardiac puncture, allowed to clot at room temperature for 1 h, centrifuged for 15 min at 1,0009g and plasma was removed. The colon of each mouse was removed, measured, flushed with ice-cold PBS, flayed and the mucosa was scraped and separated into two fractions. One fraction was flash frozen in liquid nitrogen and the other fraction was placed in RNAlater (Ambion, Grand Island, NY) and then flash frozen in liquid nitrogen.
Vitamin D Quantification
Plasma was transported to the laboratory of Dr. Bruce Hollis (Medical University of South Carolina, Department of Pediatrics) for quantification of systemic 25(OH)-vitamin D via a 25(OH)-vitamin D radioimmunoassay as described [33] .
Colitis Scoring
The colons from mice reserved for colitis scoring were removed, flushed with ice-cold PBS, flayed and Swissrolled. Colons were fixed overnight in 70 % ethanol and paraffin embedded. Five-micrometer sections were cut and stained with H&E. H&E stained slides were scored blindly by Dr. Shaoli Sun (Medical University of South Carolina, Department of Pathology) on a scale from 0 to 4 as described [34] . Briefly, grade 0 was normal colon tissue, grade 1 was mild focal ulceration, grade 2 was moderate multifocal ulceration, grade 3 was moderate to severe multifocal ulceration and grade 4 was widespread ulceration.
Protein Extraction and Immunobloting
The colonic mucosa fraction not placed in RNA later was homogenized in 500 lL of T-Per tissue protein extraction (Thermo Scientific, Rockport, IL) and 0.05 % protease inhibitor cocktail via sonification. The homogenate was centrifuged at 10,0009g for 5 min and the supernatant was collected. Protein purity and concentration was quantified with a GE Nanovue. Protein samples (standardized to 50 lg of nuclear protein per lane) were mixed in loading buffer containing 2 % sodium dodecyl sulfate and 10 % bmercaptoethanol. Protein was denatured at 95°C for 5 min and then run in a 10 % polyacrylamide gel with a Precision Plus Protein Standard (BioRad, Hercules, CA). Proteins were transferred to a nitrocellulose membrane at 65 mA for 4 h. The blot was saturated in PBS and 0.1 % Tween 20 (PBS-T buffer) containing 10 % nonfat dry milk at 48 C for a minimum of 1 h and then incubated overnight at 4°C with the appropriate primary antibody. Antibodies used were anti-VDR, -RXRa (Millipore, Billerica, MA) and -GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA) as a loading control diluted 1:1,000-1:5,000 in 5 % nonfat dry milk. Blots were washed three times in PBS-T for 10 min at room temperature before incubating with the appropriate horseradish peroxidase secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:10,000-1:20,000 in 5 % nonfat dry milk for 2 h at room temperature. Blots were then washed three times in PBS-T for 10 min each at room temperature and detection of protein was performed using West Pico and Femto blot detection reagents (Thermo Scientific, Pittsburgh, PA). Films were scanned and bands were quantified using Image J software. Proteins of interest were normalized to GAPDH for total cellular protein.
RNA Extraction and Real-Time PCR RNA was isolated from the mucosa scraping placed in RNAlater with a miRNAeasy kit (Qiagen, Valencia, CA) according to manufacturer's instructions and each sample was resuspended in 40 lL RNAse-free water. The RNA purity and concentration was quantified with a GE Nanovue. Reactions were set up in duplicate for each sample. 
Statistical Analysis
For the statistical analysis of immunoblotting and real time PCR data, expression levels from the animals were averaged in the control or treated group and the averages of treated and control mice were compared via a Student's t test. To perform comparisons between the wild-type and heterozygote mice, a two-way ANOVA with interactions was used to evaluate differences due to genotype.
Results
Acute Challenge with AOM/DSS Results in Colitis in Heterozygote and Wild-Type Littermates
To study murine colitis, the widely accepted AOM/DSS murine model of UC was utilized. Mice were injected at 6 weeks of age intraperitoneally with 10 mg/kg of AOM and, after 7 days of recovery, were challenged with 2 % DSS for 7 days. This resulted in a decrease in body weight for heterozygote and wild-type mice associated with the DSS challenge with the difference observed between the heterozygotes and wild-types not statistically significant (Fig. 1) . Gross blood loss, an indicator of disease severity, became apparent for both heterozygote and wild-type mice on the sixth day of the DSS challenge, 2 days prior to sacrifice. Both heterozygote and wild-type mice had a statistically significant decrease in systemic vitamin D. The average systemic vitamin D level for treated wild-type mice was 19.45 ± 7.05 ng/mL with the average for control wild-type mice being 25.65 ± 1.68 ng/mL (p = 0.03). The average for treated heterozygotes was 16.5 ± 2.26 ng/mL with the average for control heterozygotes being 25.45 ± 6.56 ng/mL (p = 0.03). The decreases measured in heterozygote and wild-type mice were not statistically different from one another. There was no statistical difference in the colitis scoring between the heterozygote and wild-type mice (data not shown).
Acute Colitis Results in Increased Inflammatory Maker Expression in Heterozygotes as Compared to Their Wild-Type Littermates
To analyze expression of receptors and inflammatory markers, real time PCR results or immunoblots were quantified and the average expression levels were calculated for the heterozygote and wild-type mice. Control heterozygote mice demonstrated a significant downregulation of RXRa mRNA (p = 0.0004) and protein trended toward downrgulation, compared to wild-type mice (Fig. 2a, b) . RXRa mRNA was not significantly downregulated in heterozygote or wild-type treated mice. VDR mRNA was significantly downregulated in both heterozygote and wild-type treated mice and TNFa and COX-2 expression were significantly upregulated in both heterozygote and wild-type treated mice. There was no statistical difference in the upregulation or downregulation in these genes when heterozygotes were compared to wild-type mice. Snail and Snail2 mRNA were both statistically upregulated in the heterozygote treated mice (Fig. 3a, b) . RXRa protein was not significantly downregulated in either the treated heterozygote or wild-type mice whereas VDR protein was significantly downregulated in treated heterozygote and wild-type mice with no statistical difference between the heterozygote and wild-type mice (Fig. 4) .
Discussion
The anti-inflammatory role of vitamin D has been well established [35] [36] [37] [38] and its role in colitis development and progression is being explored. This is highlighted by our Fig. 1 Acute AOM/DSS colitis results in a weight loss for heterozygote and wild-type mice. To model an acute colitis, 10 mg/kg of AOM (treated) or saline (control) was injected into mice intraperitoneally at 6 weeks of age. Mice were allowed to recover for 1 week and then treated mice were challenged with 2 %DSS. Wild-type and heterozygote mice challenged with AOM/DSS experience nonsignificant difference in weight loss associated with the DSS challenge recent finding that a vitamin D deficient diet results in a more severe acute murine colitis with increased mortality, inflammatory signaling and receptor downregulation [20] Although VDR's requirement for RXRa has long been recognized [7] , the effects that a reduction in the availability of RXRa would have on vitamin D's regulation of inflammatory signaling in the context of acute AOM/ DSS murine colitis have yet to be determined. As RXRa knockout mice are embryonic lethal likely due to heart malformations [39] , RXRa ?/-mice are an ideal system in which to study the inflammatory effects that would result due to a reduction in the availability of RXRa. We found that heterozygote mice had decreased RXRa mRNA but not protein compared to wild-type mice. The lack of RXRa protein downregulation in our study is likely due to the small sample size. The AOM/DSS model is an accepted model for colitis-associated-cancer. DSS or AOM/DSS can be used acutely to produce an acute colitis; however, we and others have found that adding AOM to the regime can enhance lesion progression [40] .
When challenged with acute AOM/DSS colitis, heterozygote mice and their wild-type littermates did not react grossly different to the AOM/DSS challenge as the weight loss and colitis scores observed in heterozygote and wildtype mice were not statistically significant from one another. RXRa mRNA and protein were not found to be significantly downregulated in either the heterozygote or wild-type treated mice. However, as RXRa ?/-mice express less basal RXRa mRNA and likely protein, this degree of downregulation in treated mice may be more significant than in wildtype mice. Although the only statistically significant difference between heterozygote and wild-type mice was the upregulation of Snail and Snail2 mRNA in heterozygote mice, this could have important ramifications.
Snail and Snail2 are transcription factors that are stabilized by inflammatory signaling [24] [25] [26] [27] [28] and are known to downregulate VDR expression [21] [22] [23] . They are expressed in the ulcerated tissue of UC patients corresponding with a localized downregulation of VDR expression [22, 29, 30] . The early upregulation of Snail and Snail2 observed in this study in heterozygote mice could lead to a vicious inflammatory cycle. If Snail and Snail2 are overexpressed early, as found in this acute colitis model which only lasted 2 weeks, this could lead to a further transcriptional downregulation of VDR that would incapacitate the anti-inflammatory effects of vitamin D, lead to increased inflammatory signaling as well as subsequent increased Snail and Snail2 expression. VDR was downregulated in both heterozygote and wild-type mice, whereas Snail and Snail2 were only upregulated in heterozygote mice, indicating another mechanism for early VDR downregulation was likely also at play; however, the upregulation of Snail and Snail2 could lead to further VDR downregulation in heterozygote mice if the model was allowed to progress. As RXRa does have numerous signaling partners, it is unclear if upregulation of Snail and Snail2 observed in our experiments are solely due to the reduced ability of vitamin D to quell the inflammatory cascade; however, it remains a valid explanation. Perhaps, if a chronic model of colitis or a CAC model was investigated, heterozygote mice would begin to demonstrate increased gross colitis symptomology, or, due to the early upregulation of Snail and Snail2, an increased downregulation of VDR. One limitation of this study is the lack of an in vitro model for colitis. As colitis is a disease state that involves epithelial cells, stroma and inflammatory cells, it cannot simply be modeled in vitro. The availability of an in vitro model would allow for a further investigation into the mechanism of VDR downregulation observed in our in vivo model. With this limitation, we can only conclude from our experiments, the importance of RXRa in modulating acute colitis development.
Our lab has shown that RXRa is downregulated in colon cancer cell lines, human CRC [19] and murine colitis and CAC [20] , yet a definite mechanism of downregulation has yet to emerge. Vitamin A deficiency and administration acute phase reactants have shown to downregulate RXRa in mice, but these mechanisms have yet to be fully explained [41] [42] [43] [44] [45] . If a mechanism through which RXRa is silenced is identified, targeted approaches to increasing RXRa could be explored, thus potentially restoring the signaling of vitamin D and PPARk ligands, allowing vitamin D to control inflammation and decrease the upregulation of Snail and Snail2. This may have clinical applicability in colon cancers that are unresponsive to vitamin D interventions [46] or if PPARk ligands are ever translated to the clinic. These experiments demonstrate, for the first time, the importance that VDR's signaling partner, RXRa, has in regulating inflammation in the setting of acute murine colitis.
